Xintela AB (FRA:1XT) Days Payable: 0.00 (As of Mar. 2026)

What is Xintela AB Days Payable?

Xintela AB FRA:1XT +6.25% 8 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates FRA:1XT with a GF Score™ of 8/100. The stock has 2 warning signs investors should review. Among 702 Biotechnology companies, Xintela AB ranks worse than 142450% on this metric.

Xintela AB's average Accounts Payable for the three months ended in Mar. 2026 was €0.52 Mil. Xintela AB's Cost of Goods Sold for the three months ended in Mar. 2026 was €0.00 Mil.

The historical rank and industry rank for Xintela AB's Days Payable or its related term are showing as below:

FRA:1XT's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.56
* Ranked among companies with meaningful Days Payable only.

Xintela AB's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Xintela AB Days Payable Related Terms

Xintela AB Days Payable Historical Data

* Premium members only.

The historical data trend for Xintela AB's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xintela AB Days Payable Chart

Xintela AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

0.00

Xintela AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

FRA:1XT vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Xintela AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xintela AB Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xintela AB's Days Payable distribution charts can be found below:

* The bar in red indicates where Xintela AB's Days Payable falls into.

Save Embed

8GF Score

Xintela AB FRA:1XT

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Xintela AB Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Xintela AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (0.247	+	0.473)	/	2 )	/	0	*	365
=	0.36					/	0	*	365
=	N/A

Xintela AB's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (0.473	+	0.573)	/	2 )	/	0	*	365 / 4
=	0.523					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Xintela AB (FRA:1XT) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Xintela AB and its competitors. According to the industry distribution chart, Xintela AB ranks #999999 out of 702 companies in the Biotechnology industry.

Is Xintela AB's Days Payable too high?

Xintela AB's current Days Payable is 0.00. Based on the distribution chart, Xintela AB ranks #999999 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xintela AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.

How does Xintela AB's Days Payable compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Xintela AB ranks #999999 out of 702 companies for Days Payable. This places Xintela AB in the lower half of its industry. The industry median Days Payable is 113.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Xintela AB and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xintela AB's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Xintela AB stock overvalued right now?

Xintela AB (FRA:1XT) has a current Days Payable of 0.00. The current Days Payable is 0.00. Xintela AB's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Xintela AB (FRA:1XT), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xintela AB Business Description

Industry Healthcare Biotechnology

Comparable Companies XSAT:DEX OSTO:INIT XSAT:ABERA OSTO:XBRANE OSTO:ISOFOL OSTO:ELIC OSTO:KDV OSTO:NICA OSTO:DMYD B OSTO:ACTI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges XINT:Sweden

Address Medicon Village, Lund, SWE, 223 81

Website https://www.xintela.se

Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.

8GF Score

Get the complete analysis for FRA:1XT

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01

Price

View FRA:1XT Analysis

See Days Payable data for all stocks →